RP7214
/ Rhizen
- LARVOL DELTA
Home
Next
Prev
1 to 15
Of
15
Go to page
1
October 31, 2022
Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1/2 | N=0 | Withdrawn | Sponsor: Rhizen Pharmaceuticals SA | N=36 ➔ 0 | Not yet recruiting ➔ Withdrawn
Combination therapy • Enrollment change • Trial withdrawal • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology
October 12, 2022
A First in man study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RP7214, a Dihydroorotate Dehydrogenase (DHODH) inhibitor in Healthy Subjects.
(PubMed, Br J Clin Pharmacol)
- P1 | "Inhibition of DHODH, as evidenced by increased DHO levels was observed, confirming target engagement. The high systemic exposure with a favourable safety profile shows potential for the development of RP7214 in SARS-CoV-2 and acute myeloid leukemia (NCT04680429)."
Clinical • Journal • PK/PD data • Acute Myelogenous Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Novel Coronavirus Disease • Oncology • Respiratory Diseases
August 18, 2022
Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1/2 | N=36 | Not yet recruiting | Sponsor: Rhizen Pharmaceuticals SA | Initiation date: Apr 2022 ➔ Jan 2023
Combination therapy • Trial initiation date • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology
April 21, 2022
Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.
(clinicaltrials.gov)
- P2 | N=163 | Completed | Sponsor: Rhizen Pharmaceuticals SA | Recruiting ➔ Completed
Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD8 • CRP • IL6
March 09, 2022
Activity of RP7214, a novel, selective, and potent small molecule inhibitor of DHODH, in AML
(AACR 2022)
- "Herein, we describe the efficacy of RP7214 as a single agent and in combination with standard of care drugs in preclinical models of AML Cell viability of AML cell lines (U937, HL-60, THP-1, and KG-1) following incubation with RP7214 as a single agent or in combination with Azacytidine or Venetolcax for 72 h was determined in an MTT-based assay...Similarly, combination of 3 µM-RP7214 with 3 nM Venetoclax demonstrated 15% (P < 0.05) inhibition of cell growth compared to single agents in MV-4-11 cell line. Results demonstrate the utility of RP7214 as a single agent and in combination with standard of care drugs in inducing apoptosis and promoting differentiation to fully mature cells in AML. A Phase 2a trial in AML patients is planned."
Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • ITGAM
April 09, 2022
Rhizen Pharmaceuticals AG Presents Data on Its Differentiated PARP and DHODH Inhibitor Programs at AACR 2022
(Businesswire)
- "Rhizen Pharmaceuticals AG...announced the release of data on its differentiated next-generation clinical-stage PARP (Poly ADP-Ribose Polymerase) and DHODH (DiHydro Orotate DeHydrogenase) inhibitor programs at the American Association for Cancer Research (AACR) 2022 Annual Meeting. Rhizen’s poster presentations describe the preclinical characterization and differentiated features of its novel PARP inhibitor (RP12146) and preclinical data supporting the broad positioning of its DHODH inhibitor (RP7214) in AML."
Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Solid Tumor
February 18, 2022
Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1/2 | N=36 | Not yet recruiting | Sponsor: Rhizen Pharmaceuticals SA
Combination therapy • New P1/2 trial • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology
September 22, 2021
Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.
(clinicaltrials.gov)
- P2; N=204; Recruiting; Sponsor: Rhizen Pharmaceuticals SA; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD8 • CRP • IL6 • PCR
August 18, 2021
A Single and Multiple Ascending and Food Effect Study of RP7214, a DHODH Inhibitor in Healthy Adult Subjects
(clinicaltrials.gov)
- P1; N=42; Completed; Sponsor: Rhizen Pharmaceuticals SA; Active, not recruiting ➔ Completed
Trial completion
August 16, 2021
Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild SARS-CoV-2 Infection.
(clinicaltrials.gov)
- P2; N=204; Not yet recruiting; Sponsor: Rhizen Pharmaceuticals SA
New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PCR
July 21, 2021
A Single and Multiple Ascending and Food Effect Study of RP7214, a DHODH Inhibitor in Healthy Adult Subjects
(clinicaltrials.gov)
- P1; N=42; Active, not recruiting; Sponsor: Rhizen Pharmaceuticals SA; Recruiting ➔ Active, not recruiting
Clinical • Enrollment closed
April 23, 2021
A Single and Multiple Ascending and Food Effect Study of RP7214, a DHODH Inhibitor in Healthy Adult Subjects
(clinicaltrials.gov)
- P1; N=42; Recruiting; Sponsor: Rhizen Pharmaceuticals SA; N=18 ➔ 42; Trial primary completion date: Mar 2021 ➔ Jun 2021
Clinical • Enrollment change • Trial primary completion date
December 28, 2020
A Single Oral Dose Study of RP7214, a DHODH Inhibitor in Healthy Adult Subjects
(clinicaltrials.gov)
- P1; N=18; Recruiting; Sponsor: Rhizen Pharmaceuticals SA; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open
December 23, 2020
A Single Oral Dose Study of RP7214, a DHODH Inhibitor in Healthy Adult Subjects
(clinicaltrials.gov)
- P1; N=18; Not yet recruiting; Sponsor: Rhizen Pharmaceuticals SA
Clinical • New P1 trial
December 01, 2020
Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection, Phase 1 Clinical Trial of RP7214 Set to Begin Early December 2020
(Equitybulls)
- "Rhizen Pharmaceuticals...today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to study its oral DHODH inhibitor for SARS-CoV-2 infection. The company announced that initial study shall evaluate single ascending doses of RP7214 in healthy volunteers and that dosing is expected to commence in early December 2020. The company also announces positive feedback from the FDA during its pre-IND discussion on its plans to follow-up this study with a multiple-ascending dose study in Covid-19 patients....Further, the IND-enabling preclinical studies have shown RP7214 to be orally available, safe and tolerable with predictable dose-linear pharmacokinetics."
IND • New P1 trial • Preclinical • Novel Coronavirus Disease
1 to 15
Of
15
Go to page
1